Trials / Completed
CompletedNCT05579925
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | CM310 600 mg + 300 mg, subcutaneous injection |
Timeline
- Start date
- 2022-10-07
- Primary completion
- 2023-07-28
- Completion
- 2023-07-28
- First posted
- 2022-10-14
- Last updated
- 2024-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05579925. Inclusion in this directory is not an endorsement.